Characterization and functional role of androgen-dependent PDE5 activity in the bladder
about
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasiaTadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of actionOveractive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introductionA review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunctionInfluence of sildenafil on blood oxygen saturation of the obstructed bladderPhosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.New insights into the pharmacology of the bladderPhosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV studyEffects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis.Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancerUpregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.Lower urinary-tract symptoms and testosterone in elderly menPDE5 inhibitors beyond erectile dysfunction.PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunctionPhosphodiesterase-5 expression and function in the lower urinary tract: a critical review.Promising molecular targets and biomarkers for male BPH and LUTSUrinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.Androgen Receptor Signaling in Bladder Cancer.Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management.Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.The role of the androgen receptor in the development and progression of bladder cancer.Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.Direct androgen regulation of PDE5 gene or the lack thereof.The role of phosphodiesterases in bladder pathophysiology.Tadalafil - a therapeutic option in the management of BPH-LUTS.Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia.Latest pharmacotherapy options for benign prostatic hyperplasia.Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/GPER?Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study.Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects.Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer.
P2860
Q24199135-0A75594E-843D-4A79-8288-C02CF05417ADQ26783529-F311033D-AEDF-4BB2-A5E6-C895A4B2F134Q27011502-B141CC7C-A3F3-4154-A713-0E79E8F9BF70Q33744285-B78CC050-11E9-44F8-93A1-9D7415A6A24EQ33767906-42D2ECD7-DCD0-4698-BAF7-617CC2F0C172Q33953840-778631B6-4917-404B-B329-B2F03538A066Q34112983-7110F6F4-F3F6-4150-AFCA-E5B599C3E953Q34114694-6A04668D-73DD-445B-848D-8930E94630ABQ34931019-BFAE6780-4922-45AD-A96F-C5DDF6133E29Q35183603-10AE8996-6262-492E-B20B-63CCDD118E1EQ35603121-2707B66C-480A-4E92-BF8F-1A77AD8A7ABCQ35824043-2B6A13B0-BFD6-4301-828A-FAB7DFAF880DQ35924409-CC11CEF7-AD35-48DC-A61F-EBB655B3B791Q36261347-667D627E-447F-44FF-BAE5-D75E538A4D21Q36360868-E0701FF7-3EC3-406C-9D48-D182024E09DCQ36839032-5D9C7AF9-425F-47D4-98BB-4C58F987A5B6Q36878017-CAC29A4B-D110-48DE-9A67-2DEDFD2ECCCEQ37025381-1DCF7A51-2C7C-4386-9261-719162D48FAAQ37030511-87D0C1FB-6754-4A9B-8079-49B01BD699AFQ37305843-79395345-9E51-4DCC-891E-82A4330757ABQ37340520-628640B3-327E-4695-A75F-028EF0F4F841Q37364472-A6F484DC-2CBC-4E2C-80D0-1356F7AA0360Q37466573-134819E2-737A-4635-BE59-0365886BFAD4Q37618958-02588FD3-6066-4227-B275-050F464276A0Q37676080-BE1655A2-8BFE-4C39-B4A0-8808436A503FQ37833959-6187CFEB-AA14-43B1-A341-FDE714E9A639Q37877132-8E4A7F27-75CA-4926-82FB-16E4443FAC19Q37896170-AB2A91A3-1259-4B89-925A-9173DB47D322Q38010699-E7A72582-1F3A-4072-BB8F-ED5A4FDAC52CQ38047228-03DFE563-D626-47F1-92C4-7F61D69C5717Q38088930-2A71BD3A-9243-4BE0-B9B1-2377BA84FC16Q38106628-19161B43-15C9-4239-A1FA-780DFA22FD69Q38171532-44285A19-D7E8-4F4A-8D40-CE8A711CF645Q38220350-B70EF162-4D0F-46E5-B004-096266E9065CQ38241547-79635BCE-8658-4A1E-BB09-E5C9811A7492Q38244053-D315C892-B565-4000-AC6A-6E6D5DA515BDQ39095837-EEE424B2-5AA7-4439-A73C-E5605AB95F12Q39190285-005D4D52-AC47-40EC-86E1-D0447287C3FDQ39275983-BBC06BC9-B102-4E2E-8721-3CA9CFE8D3C1Q40590766-3191F8DB-CE36-4F95-9C49-00F3E0075924
P2860
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
description
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im März 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/03/01)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/03/01)
@nl
наукова стаття, опублікована в березні 2007
@uk
مقالة علمية (نشرت في مارس 2007)
@ar
name
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@ast
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@en
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@nl
type
label
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@ast
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@en
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@nl
prefLabel
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@ast
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@en
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@nl
P2093
P50
P356
P1433
P1476
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
@en
P2093
Benedetta Fibbi
Gabriella Barbara Vannelli
Linda Vignozzi
Marco Carini
Mario Maggi
Mirca Marini
Peter Sandner
Rosa Mancina
Sandra Filippi
P304
P356
10.1210/EN.2006-1079
P407
P577
2006-11-30T00:00:00Z